Mon, Dec 29, 2014, 9:25 AM EST - U.S. Markets open in 5 mins.

Recent

% | $
Quotes you view appear here for quick access.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

  • yassen_gregorivich yassen_gregorivich Nov 18, 2013 4:50 PM Flag

    Study results shows longer term stability, well tolerated, good news

    To summarize, the Phase 3 study of Juxtapid showed continued success in meeting primary endpoints for efficacy over a longer time horizon while keeping the same safety profile as they did at 78 weeks. This shows that longer term use continues to be effective (whereas many medications taper off substantially the longer you use them).

    So, continued effectiveness over a longer period of time, stable safety profile (same as before, just now with a longer time horizon), and continued success.

    Oh, and one person had to discontinue, who was an alcoholic, but even that provides useful data. Few medications are even remotely tolerated when an excess of alcohol is introduced. So this is no surprise.

 
AEGR
22.00Dec 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.